# A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

> **NCT01636843** · PHASE2 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 298 (actual)

## Conditions studied

- Inflammation
- Rheumatoid Arthritis

## Interventions

- **DRUG:** NNC0109-0012
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01636843
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-30
- **Primary completion:** 2014-11-10
- **Final completion:** 2014-11-10
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636843, "A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01636843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*